Circulating Immune Cell Composition and Cancer Risk: A Prospective Study Using Epigenetic Cell Count Measures
Discover our resources
Resource types
Topics
-
Download Research Article Circulating Immune Cell Composition and Cancer Risk: A Prospective Study Using Epigenetic Cell Count Measures
-
Download Research Article The impact of the Th17: Treg axis on the IgABiome across the glycemic spectrum
The impact of the Th17: Treg axis on the IgABiome across the glycemic spectrum
-
Download Research Article Urinary CD8+HLA-DR+ T Cell Abundance Non-invasively Predicts Kidney Transplant Rejection
Urinary CD8+HLA-DR+ T Cell Abundance Non-invasively Predicts Kidney Transplant Rejection
-
Download Research Article FOXP3 TSDR Measurement Could Assist Variant Classification and Diagnosis of IPEX Syndrome
FOXP3 TSDR Measurement Could Assist Variant Classification and Diagnosis of IPEX Syndrome
-
Download Poster Simultaneous Quantification of Multiple Signaling Molecules in Individual Circulating Tumor Cells (CTCs) by Multi-Color Laser Scanning Cytometry
Simultaneous Quantification of Multiple Signaling Molecules in Individual Circulating Tumor Cells (CTCs) by Multi-Color Laser Scanning Cytometry
%20by%20Multi-Color%20Laser%20Scanning%20Cytometry.jpg?width=270&height=350&name=111.%20Simultaneous%20Quantification%20of%20Multiple%20Signaling%20Molecules%20in%20Individual%20Circulating%20Tumor%20Cells%20(CTCs)%20by%20Multi-Color%20Laser%20Scanning%20Cytometry.jpg)
-
Download Poster BRAFV600E mutation analysis in circulating tumor cells
BRAFV600E mutation analysis in circulating tumor cells
-
Download Poster Characterization and Identification of Specific EGFR Mutations in Circulating Tumor Cells (CTCs) Isolated From Non-Small Cell Lung Cancer Patients Using an Antibody Independent Method, ApoStream®
Characterization and Identification of Specific EGFR Mutations in Circulating Tumor Cells (CTCs) Isolated From Non-Small Cell Lung Cancer Patients Using an Antibody Independent Method, ApoStream®
-
Download Poster Etirinotecan pegol Target-Specific Pharmacodynamic (PD) Biomarkers Measured in Circulating Tumor Cells (CTCs) from Patients in the Phase 3 BEACON Study in Patients with
Etirinotecan pegol Target-Specific Pharmacodynamic (PD) Biomarkers Measured in Circulating Tumor Cells (CTCs) from Patients in the Phase 3 BEACON Study in Patients with
%20Biomarkers%20Measured%20in%20Circulating%20Tumor%20Cells%20(CTCs)%20from%20Patients%20in%20the%20Phase%203%20BEACON%20Study%20in%20Patients%20with.jpg?width=270&height=350&name=108.%20Etirinotecan%20pegol%20Target-Specific%20Pharmacodynamic%20(PD)%20Biomarkers%20Measured%20in%20Circulating%20Tumor%20Cells%20(CTCs)%20from%20Patients%20in%20the%20Phase%203%20BEACON%20Study%20in%20Patients%20with.jpg)
